Evaluating how stress reduction affects heart health

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study investigates the effects of an 8-week mindfulness-based stress reduction program on atherosclerotic plaque inflammation in adults experiencing high levels of psychosocial stress. Participants will undergo baseline imaging using positron emission tomography (PET) and will be randomized into either a stress-reduction intervention group or a control group. The study aims to assess changes in arterial inflammation through follow-up imaging after the intervention. The approach combines understanding stress physiology with practical relaxation techniques and cognitive behavioral skills.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* • Aged between 30-65 years

  * Identifies as having increased levels of stress and/or has a Perceived Stress Scale (PSS) score \>5 at baseline, and is interested in participating

Exclusion Criteria:

* Perceived Stress Scale (PSS) score \<6

Where it's running

• Massachusetts General Hospital
  Boston, Massachusetts, United States Recruiting

Study contacts

• Principal investigator: Ahmed Tawakol, MD — Mgh
• Study coordinator: Ahmed Tawakol, MD
• Email: atawakol@mgh.harvard.edu
• Phone: 6177243699

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pudendal artery plaque and erectile dysfunction in men with heart disease

  A small study tests whether plaque in the internal pudendal arteries is linked to erectile function in men with coronary artery disease who are undergoing coronary angiography.

  Recruiting Hospital Central Militar · Mexico City, Mexico City · NCT07856199

• VERVE-102 for adults with or at high risk for heart disease

  This study tests whether VERVE-102 can lower bad cholesterol (LDL-C) compared with a placebo in adults with plaque buildup or high risk for it.

  Recruiting Phase 2 Verve Therapeutics, Inc. · DeSoto, Texas · NCT07839936

• Colchicine for preventing cardiovascular disease in adults with type 2 diabetes

  A 24-week study will test whether low-dose colchicine can help protect blood vessels in adults with type 2 diabetes who have not yet developed artery disease, compared with a placebo.

  Recruiting Phase 2 Tan Tock Seng Hospital · Singapore, Singapore · NCT07837934

• Clazakizumab for adults with high hsCRP at risk for a heart event

  This study tests whether clazakizumab can lower inflammation and reduce cardiovascular risk in adults with high hsCRP and existing risk factors.

  Recruiting at 32 sites Phase 2 Eli Lilly and Company · Huntsville, Alabama and 45 other locations · NCT07783802

• Cilostazol and Aspirin to Prevent Heart and Brain Events in Type 2 Diabetes

  In people with type 2 diabetes and higher cardiovascular risk, researchers are testing whether taking cilostazol plus aspirin can help reduce major heart and brain events.

  Recruiting Phase 4 Seoul National University Bundang Hospital · Seongnam-si, Gyeonggi-do · NCT07719894

• Dapagliflozin to slow coronary plaque progression in type 2 diabetes

  This trial tests whether adding dapagliflozin to standard care can slow or reverse coronary plaque buildup in adults with type 2 diabetes and stable coronary disease.

  Recruiting at 2 sites Phase 4 Chinese PLA General Hospital · Beijing, Beijing Municipality and 1 other locations · NCT07614230

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.